Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;9(2):75-82.
doi: 10.1177/1758834016676011. Epub 2016 Nov 2.

A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis

Daniel H Ahn  1 , Kavya Krishna  2 , Marlo Blazer  3 , Joshua Reardon  3 , Lai Wei  4 , Christina Wu  5 , Kristen K Ciombor  2 , Anne M Noonan  2 , Sameh Mikhail  2 , Tanios Bekaii-Saab  6
Affiliations

A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis

Daniel H Ahn et al. Ther Adv Med Oncol. 2017 Feb.

Abstract

Background: Treatment with nab-paclitaxel with gemcitabine demonstrates a survival advantage when compared with single-agent gemcitabine. However, the combination is associated with significant toxicities, leading to a high rate of drug discontinuation. We implemented a modified regimen of gemcitabine and nab-paclitaxel (mGNabP) in an attempt to minimize toxicities while maintaining efficacy.

Methods: A total of 79 evaluable patients with metastatic pancreatic adenocarcinoma (mPC) treated with a modified regimen of gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) on days 1, 15 of every 28-day cycle were identified from our prospective database. A total of 57 patients received this regimen as first-line treatment and were evaluated for toxicities, progression-free survival (PFS), and overall survival (OS). Overall, 22 patients with advanced or metastatic PC treated with the modified regimen outside the first-line setting were only evaluated for toxicities.

Results: The median OS and PFS were 10 months [95% confidence interval (CI) 5.9-13 months] and 5.4 months (95% CI 4.1-7.4 months) for patients that received the modified regimen as first-line therapy. Neurotoxicity occurred in 27% with only 1.6% of patients experiencing grade ⩾3 toxicity. The incidence of grade ⩾3 neutropenia was 19%, resulting in growth factor support in 12% of patients. This rate was similar in patients who received the modified regimen for first-line treatment of mPC versus the overall group.

Conclusions: A modified regimen of biweekly nab-paclitaxel with gemcitabine is associated with a lower cost, acceptable toxicity profile and appears to be relatively effective in pancreatic cancer. Prospective randomized studies confirming its potential benefits compared with standard weekly mGNabP are warranted.

Keywords: efficacious; gemcitabine-improved toxicity; modified regimen; nab-paclitaxel; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Kaplan–Meier estimates of PFS and OS. Figure A shows the PFS in patients with mPC who received modified mGNabP in the first-line setting. Figure B shows OS for the same patient cohort. mGNabP, modified regimen of gemcitabine and nab-paclitaxel; mPC, metastatic pancreatic cancer; OS, overall survival; PFS, progression-free survival.
See this image and copyright information in PMC

References

    1. Burris H., Moore M., Andersen J., Green M., Rothenberg M., Modiano M., et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413. - PubMed
    1. Cantore M., Fiorentini G., Luppi G., Rosati G., Caudana R., Piazza E., et al. (2004) Gemcitabine versus flec regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for integrated locoregional therapy in oncology. J Chemother 16: 589–594. - PubMed
    1. Colucci G., Labianca R., Di Costanzo F., Gebbia V., Carteni G., Massidda B., et al. (2010) Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28: 1645–1651. - PubMed
    1. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., et al. (2011) Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817–1825. - PubMed
    1. Cunningham D., Chau I., Stocken D., Valle J., Smith D., Steward W., et al. (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513–5518. - PubMed

LinkOut - more resources